Chengdu Olymvax Biopharmaceuticals (SH:688319) Xin Lang Cai Jing·2025-11-27 02:15Core Viewpoint - Oulin Bio has experienced a significant stock price increase, with a 12.88% rise over the past three days, indicating strong market interest and potential investor confidence in the company's performance [1]. Company Overview - Oulin Bio, established on December 11, 2009, and listed on June 8, 2021, is located in Chengdu, Sichuan Province. The company specializes in the research, production, and sales of human vaccines [1]. - The main revenue sources for Oulin Bio include: - Tetanus vaccine: 90.99% - A and C group meningococcal polysaccharide conjugate vaccine: 4.49% - Haemophilus influenzae type b conjugate vaccine: 3.99% - Other (supplementary): 0.47% - Refined tetanus toxin raw liquid: 0.07% [1]. Fund Holdings - Oulin Bio is a significant holding for the Dongfang Urban Consumption Theme Mixed Fund (006235), which held 60,300 shares, accounting for 5.93% of the fund's net value, making it the largest position [2]. - The fund has realized a floating profit of approximately 74,700 yuan today and a total of 166,900 yuan during the three-day price increase [2]. Fund Manager Performance - The fund manager Wang Ran has a tenure of 10 years and 215 days, with a total fund size of 20.4 million yuan. The best return during his tenure is 68.26%, while the worst is -58.67% [3]. - Co-manager Cai Shangjun has been in position for 1 year and 281 days, managing a fund size of 2.76453 million yuan, with a best return of -0.48% and a worst return of -1.17% during his tenure [3].